evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

37 questions · 37 findings · 10 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 10 · 27%GRADE not reported 1 · 2.7%Very low 2 · 5.4%Low 14 · 37.8%Moderate 7 · 18.9%High 3 · 8.1%

Belimumab 10 mg/kg vs placebo

Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Participants with one or more serious infections · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in participants with one or more serious infections compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Withdrawals due to adverse events · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Belimumab 10 mg/kg vs placebo

Number of participants who died during the study · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)

Belimumab 10 mg/kg showed no clear difference in number of participants who died during the study compared with placebo (low certainty).

1 finding from 1 review